Current traction

CENTRIFUGAL PUMP DESIGN AND PARAMETRIC OPTIMIZATION (2/23 - present) ∙ Cardiost is currently finishing the volute and impeller’s design. More information will be shared once IP is filed.

JLABS (8/23 - present) ∙ Cardiost, Inc. is a resident company of Johnson & Johnson Innovation, JLABS, a premier life science incubator program. JLABS is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-enhancing health and wellness solutions to patients around the world. As a leader in innovation, JLABS helps entrepreneurs in pharmaceutical, medical device, consumer, and health tech bring healthcare solutions to patients and consumers. More information: http://jlabs.jnjinnovation.com/

NIA STARTUP CHALLENGE 2023 WINNER (8/23 - 12/23) ∙ Cardiost was one of the winners from the National Institute on Ageing (NIA) Startup Challenge Program that concluded on December 2023. Through this Challenge, NIA seeks researchers and entrepreneurs with a demonstrated need who have innovative ideas for science-driven technologies and products with the potential to increase the diversity of NIA-funded small business research and development. This Challenge is best suited to entrepreneurs who have innovative ideas for a science-driven technology or product that aligns with the NIA small business research priorities.

COLLABORATION WITH UNIVERSIDAD DE LOS ANDES, COLOMBIA (8/23 - 12/23) ∙ An additional set of simulations with Biomedical Engineering department at Universidad de los Andes (Colombia) was completed in December 2023 under the direction of Juan M. Cordovez, PhD and David Bigio. Dr. Cordovez is the director of the Bio-mathematical research laboratory (BIOMAC) at Universidad de los Andes, and Associate professor of the Department of Biomedical Engineering. Mr. Bigio has been linked to the department of Biomedical Engineering since 2016 and has been responsible for the design project courses (Capstone Design Project), which promotes knowledge in Innovation and Entrepreneurship to propose solutions to needs in health related areas in Colombia.

ATTENDANCE TO ISMCS 2023 ∙ Cardiost attended the 29th annual meeting of the International Society for Mechanical Circulatory Support (ISMCS), where a distinguished set of speakers and presenters shared their expertise and insights on all aspects of the mechanical circulatory support field. Moreover, the meeting focused on many current hot topics, such as Acute Circulatory Support, Pulmonary Support, Technology Gaps, Durable Mechanical Circulatory Support challenges, and the financial aspects of these therapies. We are looking forward to participating in ISMCS in Japan in November 2024.

CU BOULDER COLLABORATION (8/23 - present) ∙ Cardiost is also sponsoring CU Boulder’s Biomedical Engineering’s Capstone Program to develop an transcutaneous energy transfer (TET) system. The development of this induction-charging mechanism is crucial to the success of the company. Current devices rely on skin-puncturing drivelines that limit accessibility to the treatment and are prone to infections.

IN-VITRO EXPERIMENTS WITH DU (9/22 - 11/22) ∙ Cardiost has also conducted in-vitro experiments at DUCBL in late 2022 based on the above-mentioned simulations. The resulting team allowed the clinical team to validate the data that has been generated up to this point. We have developed a testing platform to examine LAUD devices. The platform can be used to test prototypes that will be designed by the Proof-of-Concept Grant obtained from the Global Business Development division of the Office of Economic Development and International Trade (OEDIT).

CFD SIMULATIONS WITH DU (6/22 - 8/22) ∙ Cardiost finished a third set of CFD simulations in late August 2022 with the University of Denver’s Cardiovascular Biomechanics Lab under the direction of Dr. Ali N. Azadani, PhD. To learn more about the results please visit our CFD Simulations section. Cardiost has ongoing Master Research Agreements with the different universities it has collaborations with that allow us to retain a 100% of the resulting Intellectual Property. This will strenghten our R&D and provide investors and physicians with a trusted source of validation for our technology.

RESEARCH TO MARKET PROGRAM AT CSU ∙ We participated in Colorado State University’s R2M (Research to Market) program during January and February 2022. R2M allows scientific teams to experience the process of customer discovery and commercialization in a hands-on program developed to engage customers in the marketplace. We have been conducting monthly customer discovery calls on a regular basis with differente stakeholders like cardiologists, hospitals, insurance companies, and patients to better understand the customers’ pain points.

COMMERCIALIZATION PARTNERSHIP WITH INNOSPHERE VENTURES ∙ Since September 2021 we have been working with Innosphere Ventures, a nonprofit 501(c)3 incubator focused on supporting entrepreneurs who are building potential high-growth companies in software, hardware, biosciences, digital health, and cleantech learn valuable skills on how to access capital, acquire customers, build talented teams, grow top line revenue and execute on a successful company exit.